88 related articles for article (PubMed ID: 34657400)
1. Wnt pathway markers in low-grade and high-grade gliomas.
Nagy Á; Tompa M; Krabóth Z; Garzuly F; Maráczi A; Kálmán B
Ideggyogy Sz; 2021 Sep; 74(9-10):349-355. PubMed ID: 34657400
[TBL] [Abstract][Full Text] [Related]
2. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
3. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
5. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
[TBL] [Abstract][Full Text] [Related]
6. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
7. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas.
Ducray F; Mokhtari K; Crinière E; Idbaih A; Marie Y; Dehais C; Paris S; Carpentier C; Dieme MJ; Adam C; Hoang-Xuan K; Duyckaerts C; Delattre JY; Sanson M
Eur J Cancer; 2011 Mar; 47(5):802-8. PubMed ID: 21194923
[TBL] [Abstract][Full Text] [Related]
9. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
[TBL] [Abstract][Full Text] [Related]
10. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
11. Yet another utility for isocitrate dehydrogenase.1: Can it serve as an immunomarker to assess tumor margins in gliomas?
Rao S; Rajkumar A; Sundaram S; Joyce ME; Duvuru P
J Cancer Res Ther; 2020; 16(6):1476-1481. PubMed ID: 33342816
[TBL] [Abstract][Full Text] [Related]
12. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
13. Wnt pathway markers in molecular subgroups of glioblastoma.
Tompa M; Nagy A; Komoly S; Kalman B
Brain Res; 2019 Sep; 1718():114-125. PubMed ID: 31075260
[TBL] [Abstract][Full Text] [Related]
14. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
16. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
[TBL] [Abstract][Full Text] [Related]
17. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
18. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
[TBL] [Abstract][Full Text] [Related]
19. Prediction of
Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
[TBL] [Abstract][Full Text] [Related]
20. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]